February 2, 2022 11:19 AM EST
News Briefing

4SC pulls plug on do­mati­no­s­tat; Pharm­ing says le­niolis­ib meets both end­points

Josh Sullivan

The man­age­ment board of 4SC has dis­con­tin­ued its do­mati­no­s­tat pro­gram af­ter the most re­cent clin­i­cal da­ta has been re­leased, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

FDA re­jects Atara's cell ther­a­py for rare trans­plant com­pli­ca­tion, stock craters

De­part­ing FDA com­mis­sion­er: 'We're los­ing the bat­tle on mis­in­for­ma­tion'

Vac­cine patch start­up col­lects an ad­di­tion­al $16M to Se­ries A

A service from the Financial Times